By admin Posted August 13, 2020 In2020-08-132020-08-13https://sfatherapeutics.com/wp-content/uploads/2020/08/logo.pngSFAtxhttps://sfatherapeutics.com/wp-content/uploads/2020/08/client-05.jpg200px200px 0 Recent PostsSFA Therapeutics accepted to the Y-Combinator Accelerator Summer Cohort 2021SFA THERAPEUTICS, INC. ANNOUNCES START OF PHASE 1b CLINICAL TRIAL IN THE TREATMENT OF MILD-to-MODERATE PLAQUE PSORIASISSFA Therapeutics Invited to Present at Angel Venture FairFDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company’s novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC).
